| Document |
Document Title |
|
WO/2018/078005A1 |
The present invention relates to amido-substituted cyclohexane compounds of general formula (I) : in which A, R4, R6, R7, R8, R9, R10 and R11 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful...
|
|
WO/2018/067382A1 |
Methods for preparing a variety of bryostatin compounds are provided. The subject methods provide for preparation of bryostatin 1 in multi-gram quantities in a low and unprecedented number of convergent synthetic steps from commercially ...
|
|
WO/2017/102784A9 |
The present specification provides a compound of formula (I): (I) or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an RORγ and/or RORγt mediat...
|
|
WO/2018/064119A1 |
Disclosed herein are small molecule calpain modulator compositions, pharmaceutical compositions, the use and preparation thereof.
|
|
WO/2018/062778A1 |
The present disclosure relates to an organic electroluminescent device comprising a first electrode, a second electrode facing the first electrode, a light-emitting layer between the first electrode and the second electrode, and an elect...
|
|
WO/2018/055402A1 |
The present invention relates to compounds of formula (I), and salts and solvates thereof, that function as inhibitors of cell division cycle 7 (Cdc7) kinase enzyme activity: (Formula (I)) wherein X, R1, R2, and n are each as defined her...
|
|
WO/2018/053588A1 |
The present invention relates to novel compounds and their use in the prophylactic and/or therapeutic treatment of hypertension and/or fibrosis.
|
|
WO/2018/057973A1 |
Disclosed are compounds of Formula I (a) or a pharmaceutically acceptable salt, a solvate, a tautomer, an isomer or a deuterated analog thereof, wherein R4, R5, R6, R7, G1, G2 and Ring A are as described in any of the embodiments describ...
|
|
WO/2018/050477A1 |
The present invention relates to relates to novel strigolactone derivatives of formula (I), to processes for preparing these derivatives including intermediate compounds, to seeds comprising these derivatives, to plant growth regulator o...
|
|
WO/2018/033088A1 |
Provided are a five-membered ring substituted compound having xanthone as the core and applications thereof. The compound has xanthone as the parent core and is connected to an aromatic heterocyclic group, thereby breaking molecular symm...
|
|
WO/2018/033085A1 |
Disclosed are a compound using anthrone as a core and applications thereof in an organic electroluminescent component. The compound uses anthrone as a parent core, which is connected to an aromatic heterocyclic group, so that the molecul...
|
|
WO/2018/031877A1 |
Disclosed herein, in part, are fumagillol compounds and methods of use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making fumagillol compounds are provided. The compounds are contemplated to...
|
|
WO/2018/024017A1 |
The present invention relates to a preparation method for 6-fluoro-2-(epoxy-2-yl)chroman. The preparation method comprises the following steps: (1) if a compound as represented by formula (II) is in an R form, subjecting a compound as re...
|
|
WO/2018/024907A1 |
The present invention relates to novel piperidine derivatives having better cell growth inhibitory activities toward cancer cell cultures and, more particularly, PANC-1 cancer cell cultures than FK866. Accordingly, the present invention ...
|
|
WO/2018/021890A1 |
The present invention relates to a novel cromenone derivative compound having heat shock protein 27 (HSP27) inhibitory activity. The composition, a pharmaceutically acceptable salt thereof or a pharmaceutical composition containing the s...
|
|
WO/2018/015292A1 |
The present invention relates to new benzo-N-hydroxy amide compounds of formula (I) and pharmaceutically acceptable salts thereof, which show a significant inhibitory activity on the proliferation of tumor cells and specifically of cance...
|
|
WO/2018/016615A1 |
Provided is a compound represented by formula (0). (0) (RY is a C1–30 alkyl group or a C6–30 aryl group; RZ is a C1–60 N-valent group or a single bond; and RT is a C1–30 alkyl group, a C6–30 aryl group, a C2–30 alkenyl group,...
|
|
WO/2018/004202A1 |
The present invention relates to an improved method for producing a diphenylmethane derivative useful as a sodium-dependent glucose cotransporter (SGLT) inhibitor. Performed in a convergent synthesis manner in which main groups are indiv...
|
|
WO/2018/002948A1 |
In accordance with the present subject matter there is provided sugar-based compounds of formula I, methods of making such compounds, gels comprising such compounds, methods of making gels, methods of using such compounds for the contain...
|
|
WO/2017/220446A1 |
The present invention pertains generally to the field of therapeutic compounds, and more specifically to crystalline forms of 4-(5-(4,7-dimethylbenzofuran-2-yl)-1,2,4-oxadiazol-3-yl)benz
oic acid (referred to herein as "BHBA-001"), which...
|
|
WO/2017/221002A1 |
The present invention relates to a novel class of chromene-2-carboxamide compounds inhibitors of general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8 and X are as defined herein, to their use in medicine, and their use as anti-infe...
|
|
WO/2017/223491A1 |
Provided is a method of inhibiting viral replication, including contacting one or more cells that has been infected or contacted with a flavivirus with an effective amount of niclosamide, temoporfin, nitazoxanide, tizoxanide, erythrosin ...
|
|
WO/2017/223177A1 |
The present invention relates to, in part, methods and compositions for the treatment of methanogen-associated disorders such as, for example, Irritable Bowel Syndrome (IBS). Particularly, modified-release formulations comprising at leas...
|
|
WO/2017/217792A1 |
The present invention relates to an improved method for producing a diphenylmethane derivative which is effective as a sodium-dependent glucose cotransporter (SGLT) inhibitor, the method being carried out by means of a convergent synthes...
|
|
WO/2017/214024A1 |
The invention relates generally to a silvestrol molecule activated with a leaving group. The invention further relates generally to an antibody-drug conjugate comprising an antibody conjugated by a linker to one or more silvestrol drug m...
|
|
WO/2017/214423A2 |
In one aspect, the present disclosure provides analogs of thailanstatin of the formula wherein the variables are as defined herein. In another aspect, the present disclosure also provides methods of preparing the compounds disclosed here...
|
|
WO/2017/202798A1 |
The present invention provides novel compounds having the general formula (I) wherein R1 to R6, X, Y, A1 and A2 are as described herein, compositions including the compounds and methods of using the compounds.
|
|
WO/2017/203457A1 |
The present invention provides solid state forms of empagliflozin, complexes of empagliflozin with amino acids, processes for their preparation and their use in purification of empagliflozin and also provided pharmaceutical compositions ...
|
|
WO/2017/198339A1 |
The present invention relates to tetrahydropyran derivatives of formula (I) having dual pharmacological activity towards both the sigma (ο) receptor, and the μ-opioid receptor, to processes of preparation of such compounds, to pharmace...
|
|
WO/2017/195113A1 |
Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infect...
|
|
WO/2017/192929A1 |
The invention provides substituted pyrrolo[1,2-α]triazine compounds, related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gauche...
|
|
WO/2017/187321A1 |
The present invention provides for compounds of formula (I), wherein R1, m, Z, G1, R2, and R3 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment ...
|
|
WO/2017/189953A1 |
Compositions comprising polymers comprising one or more ketal, monothioketal, and/or thioketal bonds are provided, as well as related methods and kits. In some embodiments, a polymer may comprise one or more repeat units comprising one o...
|
|
WO/2017/181383A1 |
A compound of Formula (I) or (II), for treating or preventing an HCV infection in a subject.
|
|
WO/2017/184545A1 |
The present invention relates generally to processes for converting fructose-containing feedstocks to a product comprising 5-(hydroxymethyl)furfural (HMF) and water in the presence of water, solvent and an acid catalyst. In some embodime...
|
|
WO/2017/178510A1 |
The present invention relates to arylamide derivatives having dual pharmacological activity towards both the α2δ subunit, in particular the α2δ-1 subunit,of the voltage-gated calcium channel and the µ-opioid receptor, to processes o...
|
|
WO/2017/178582A1 |
The present invention relates to compounds of Formula (I), or an agronomically acceptable salt of said compounds wherein A1, R1, Ra, Rb, Rc and Rd are as defined herein. The invention further relates to herbicidal compositions which comp...
|
|
WO/2017/174620A1 |
The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy.
|
|
WO/2017/165822A1 |
A compound, or a stereoisomer, pharmaceutically acceptable salt, or ester thereof, according to formula (III) or according to Table A, a pharmaceutical composition comprising said compound and at least one pharmaceutically acceptable add...
|
|
WO/2017/161095A1 |
Provided herein are rigid macrocycles comprising a first redox-active subunit and a second redox-active subunit, wherein the first redox-active unit and the second redox-active unit are different subunits. Also provided herein are method...
|
|
WO/2017/156454A1 |
There are provided inter alia stable anti-cancer compounds and splice modulators and methods of synthesis and use thereof.
|
|
WO/2017/149551A1 |
The present invention relates to new generation of aurone alkaloid agents, their method of preparation and their use as drugs for treatment of tuberculosis.
|
|
WO/2017/144639A1 |
Compounds of formula (I) wherein A, R, W, Q, n and m have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.
|
|
WO/2017/140728A1 |
The present invention relates to lactam derivatives of formula (I) for use as medicaments as well as pharmaceutical compositions comprising these compounds, particularly for use as inhibitors of the bromodomain-containing protein TAF1 (i...
|
|
WO/2017/141202A1 |
The present invention relates to a crystalline Form A of complex of Empagliflozin with L-Proline and process for preparation thereof. The present invention further relates to a method of preparing pure crystalline Empagliflozin via forma...
|
|
WO/2017/137319A1 |
The present invention relates to compounds of the general formula (I), in which Q, V, T, W, X, Y, and A have the meanings given in the description, and to the use thereof for controlling animal pests.
|
|
WO/2017/137895A1 |
The subject-matter of the present invention relates to the synthesis of new dendrimeric molecules based on polyhydroxylated pyrrolidines obtained by means of Click Chemistry reactions. The proposed molecules inhibit the enzymes N-acetylg...
|
|
WO/2017/137339A1 |
The present invention relates to compounds of the general formula (I), where to Q, V, T, W, X, Y, and A have the meanings given in the description, and to the use thereof for controlling animal pests.
|
|
WO/2017/137338A1 |
The present invention relates to compounds of the general formula (I), wherein Q, V, T, W, X, Y and A have the meanings given in the description, and to the use thereof for controlling animal pests.
|
|
WO/2017/125900A1 |
The present invention relates to a novel process for the synthesis of the intermediate compounds constituted by chromanyl haloketones of formula III and 6-fluoro-2-(oxiran-2-yl) chromans of formula I. The intermediates thus obtained can ...
|
